Vielight News

Volume 2 Issue 8 August 2018

"We are now all connected to the Internet, like Neurons in a giant brain."
*the late **Stephen Hawking**, Theoretical Physicist*

Vielight readies for pivotal Alzheimer trial

Gold-standard clinical trial directs attention to a non-pharmaceutical intervention for Alzheimer

AFTER A year of preparation, the pivotal clinical trial to investigate the Vielight Neuro RX Gamma for moderate to severe Alzheimer's Disease is expected to start recruiting participants in the next few months.

The clinical trial will be randomized double-blind placebo-controlled involving 228 participants in eight clinical sites in North America. The principal site is St Michael's Hospital in Toronto, with Dr. Corrine Fischer, Associate Professor of Geriatric Psychiatry at the University of Toronto, being the principal investigator.

The study protocol is approved by Health Canada, while the Food and Drug Administration (FDA) has reviewed the pre-submissions.

The study comes at an important time, after the repeated failures of drug trials. An estimated 47 million dementia patients around the world await a treatment that can rescue them from this fatal disease.

Vielight offers the patent-pending Neuro RX Gamma as a solution based on photobiomodulation. In a clinical case report conducted in 2014-2016 and published in 2017, an early prototype of the Neuro demonstrated that significant recovery was possible for Alzheimer.

Dr. Corrine Fischer, Principal Investigator

Further clinical case and anecdotal reports showed more significant improvements with the Gamma, pushing the company to sponsor a rigorously controlled pilot study of 40 participants in Ontario, Canada, that is still ongoing and expected to complete in spring 2019. This pivotal trial is a follow-through study expected to take three years to complete.

"We are taking a completely different approach to address Alzheimer's Disease," Dr. Lew Lim, Founder and CEO of Vielight, explains. "Instead of targeting specific molecules to modify the disease or specific neurotransmitter activities to treat symptoms, we are treating the powerhouses of the cells - the mitochondria. In the meantime, we recognize that the underlying pathology is present in brain network aberrations. We deliver certain qualities in near-infrared light that could correct these network aberrations."

Dr. Lim adds, "We are taking on a huge challenge as we are a young company that is neither funded by outside investments nor have received any grants. We depend entirely on innovation and on sales of our proprietary consumer general wellness products to see us through. This immense undertaking is worthwhile, considering the depth and breadth of suffering and financial stress that this terrible disease brings upon millions worldwide."

For more information about participating in the clinical trials, please visit http://vielight.com/AD-trial in the coming week

Contact Us:
Editor: Edward D'Mello; edward@vielight.com; North America - +1-877-355-8012; International: +1-647-201-5499;
Visit www.vielight.com for regular updates

UCSF scientist points to PBM for dementia cure

Dr. Linda Chao's findings reaffirm Vielight Neuro's effect on dementia patients

PHOTOBIOMODULATION (PBM) has the potential to treat Alzheimer's Disease, according to Dr. Linda L. Chao, from the University of California San Francisco and San Francisco Veteran Affairs Medical Center.

Speaking recently at the Alzheimer's Association International Conference (AAIC) held in Chicago, Dr. Chao highlighted the potential of PBM in treating people with dementia. AAIC is the world's largest gathering of researchers from around the world focused on Alzheimer's and other forms of dementia.

Dr. Chao, a Professor in the Department of Radiology and Biomedical Imaging and in the Department of Psychiatry at the University of California San Francisco (UCSF) and a research biologist at the San Francisco Veteran Affairs, has been working with Gulf War veterans for more than a decade now. She was the first researcher to add fMRI and ASL imaging to a PBM clinical study on dementia.

She presented her findings in a clinical trial with PBM devices at the UCSF Veterans Hospital. "We studied eight patients with dementia, where four were randomly selected to usual care. They just went about their usual activities for 12 weeks while we assessed them. The other four received the photobiomodulation treatment with the Vielight device for 12 weeks," she said.

Significantly, Chao found that after 12 weeks, the patients who were randomized to receive PBM showed improved cognition, whereas the patients who were selected for usual care, showed a decline in cognition.

Dr. Linda Chao speaking at the event

"Imaging-wise, there was evidence of increased cerebral blood flow and increased functional connectivity in the patients receiving treatment with the Vielight Gamma. The results reaffirm the success of an earlier published study, suggesting that this warrants further research. Photobiomodulation has the potential as safe, non-pharmacological intervention that can be used to treat patients with dementia in their homes," she elaborated.

Dr. Linda Chao's paper is pending publication.

Dr. Lim to present at NAALT conference

THE NORTH American Association for PhotobiomodulAtion Therapy (NAALT) will hold its annual conference from August 17-19, 2018 in Detroit, United States.

The event will bring together researchers and clinicians from around the world, including Canada, United States, Mexico, Brazil and Argentina, to present how photobiomodulation (PBM) therapy is being used to treat pain and to accelerate tissue healing of patient's around the world.

Vielight attaches great significance to events such as NAALT, where top PBM researchers gather to share their findings. This year, the NAALT conference will put the spotlight on painful medical conditions, including arthritis joints, neuropathic pain, sports injuries, brain conditions and pain in the back and neck.

Dr. Lew Lim, Founder and CEO of Vielight, will be presenting a talk called "New Evidence Presents New Ways for Transcranial Photobiomodulation to Improve Brain Functions".

He says, "People interested in what is new for improving brain functions would want to attend this event."

Dr. Lim will present the latest discoveries and content, including significant investigation findings that could lead to an improved brain.

Vielight will also have a booth at exhibition on the sidelines of the NAALT conference, where it will showcase a prototype of the highly anticipated Neuro Pro.

Vielight to participate in Toronto conference on ageing

THIS YEAR, Toronto will be hosting the Global Conference on Ageing 2018, to be held from August 8-10, at the Chelsea Hotel, in Toronto.

Hosted by the International Federation of Ageing (IFA), the event will bring together delegates from more than 70 countries to address some of the most pressing healthcare challenges facing the rapidly growing elderly population.

Vielight will be making its debut at this year's prestigious event, where it will be showcasing its photobiomodulation solutions, at an exhibition held alongside the conference.

The IFA is a global non-governmental organization with a membership base comprising government, NGOs, academics, industry, and individuals in 70 countries. This year's conference will revolve around four key themes related to the field of ageing, and will feature prominent experts presenting and discussing critical issues.

The theme of IFA's 14th Global Conference, "Towards a Decade of Healthy Ageing – From Evidence to Action," is in response to the World Health Organization (WHO) Global Report on Ageing and Health and the subsequent goals of the WHO Global Strategy and Action Plan (2016).